First, a sensitive and specific anti-EpCAM mAb, EpMab-16, was developed, which exhibited high reactivity for colorectal adenocarcinoma by flow cytometry, western blotting and immunohistochemical analyses. Here, EPCAM is linked to colorectal adenocarcinoma.